{
  "figure_1": "Pooled seroconversion rates of hematologic malignancy patients with treatment and those without treatment were calculated from studies with disaggregated data on treatment.",
  "figure_2": "CLL chronic lymphocytic leukemia, HL Hodgkin lymphoma, Leukemia acute leukemia, MDS myelodysplastic syndrome, MM multiple myeloma, MPN myeloproliferative neoplasms, NHL non-Hodgkin lymphoma.",
  "figure_3": "The pooled analysis of 21 studies containing 1518 patients with hematologic malignancies showed that the pooled seroconversion rate after booster vaccination was 40.5% (95% confidence interval [CI], 33.0–48.4%).",
  "figure_4": "The pooled analysis of 21 studies containing 2011 patients with hematologic malignancies showed that the pooled proportion of neutralizing antibody development was 52.8% (95% confident interval [CI], 45.8–59.7%).",
  "figure_5": "The pooled analysis of 17 studies containing 872 patients with hematologic malignancies showed that the pooled proportion of cellular immune responses was 66.6% (95% confidence interval [CI], 57.1–74.9%)."
}